Current Status in Rechallenge of Immunotherapy

The treatment of malignant tumors has entered the era of immunotherapy, and immune checkpoint inhibitors (ICIs) have brought significant benefits to patients. However, some patients are required to discontinue treatment with ICIs owing to factors such as disease progression and intolerable side effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Han, Wang, Ke, Jia, Rong, Zeng, Zi-Xun, Zhu, Min, Deng, Yuan-Le, Xiong, Zhu-Juan, Tang, Jian-Ning, Xie, Hua, Wang, Yi, Zhang, Peng, Zhou, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197886/
https://www.ncbi.nlm.nih.gov/pubmed/37215995
http://dx.doi.org/10.7150/ijbs.82776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197886/
https://www.ncbi.nlm.nih.gov/pubmed/37215995
http://dx.doi.org/10.7150/ijbs.82776

Ejemplares similares